nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—DRD5—eyelid—bone cancer	0.0684	0.43	CbGeAlD
Zuclopenthixol—HRH1—nose—bone cancer	0.0227	0.143	CbGeAlD
Zuclopenthixol—HTR2A—trigeminal nerve—bone cancer	0.0148	0.0934	CbGeAlD
Zuclopenthixol—HTR2A—cranial nerve—bone cancer	0.0106	0.0666	CbGeAlD
Zuclopenthixol—HTR2A—vertebral column—bone cancer	0.0104	0.0653	CbGeAlD
Zuclopenthixol—HTR2A—hindlimb—bone cancer	0.00892	0.0561	CbGeAlD
Zuclopenthixol—HTR2A—appendage—bone cancer	0.00765	0.0481	CbGeAlD
Zuclopenthixol—Domperidone—CYP3A4—bone cancer	0.00265	0.173	CrCbGaD
Zuclopenthixol—HRH1—connective tissue—bone cancer	0.00261	0.0164	CbGeAlD
Zuclopenthixol—ADRA2A—connective tissue—bone cancer	0.00257	0.0162	CbGeAlD
Zuclopenthixol—Skin disorder—Cisplatin—bone cancer	0.00231	0.0028	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Cisplatin—bone cancer	0.0023	0.00278	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Epirubicin—bone cancer	0.00229	0.00278	CcSEcCtD
Zuclopenthixol—Eosinophilia—Methotrexate—bone cancer	0.00227	0.00275	CcSEcCtD
Zuclopenthixol—Anorexia—Cisplatin—bone cancer	0.00226	0.00274	CcSEcCtD
Zuclopenthixol—Migraine—Doxorubicin—bone cancer	0.00226	0.00274	CcSEcCtD
Zuclopenthixol—Breast disorder—Epirubicin—bone cancer	0.00224	0.00272	CcSEcCtD
Zuclopenthixol—Hypotension—Cisplatin—bone cancer	0.00222	0.00269	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Epirubicin—bone cancer	0.00222	0.00269	CcSEcCtD
Zuclopenthixol—Nefazodone—CYP3A4—bone cancer	0.0022	0.144	CrCbGaD
Zuclopenthixol—Alanine aminotransferase increased—Epirubicin—bone cancer	0.00219	0.00265	CcSEcCtD
Zuclopenthixol—HTR2A—connective tissue—bone cancer	0.00218	0.0137	CbGeAlD
Zuclopenthixol—Pancytopenia—Methotrexate—bone cancer	0.00218	0.00264	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00216	0.00262	CcSEcCtD
Zuclopenthixol—Ataxia—Doxorubicin—bone cancer	0.00216	0.00262	CcSEcCtD
Zuclopenthixol—Neutropenia—Methotrexate—bone cancer	0.00214	0.0026	CcSEcCtD
Zuclopenthixol—Dysuria—Methotrexate—bone cancer	0.00214	0.0026	CcSEcCtD
Zuclopenthixol—Paraesthesia—Cisplatin—bone cancer	0.00213	0.00258	CcSEcCtD
Zuclopenthixol—Eosinophilia—Epirubicin—bone cancer	0.00212	0.00257	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Doxorubicin—bone cancer	0.00212	0.00257	CcSEcCtD
Zuclopenthixol—Dyspnoea—Cisplatin—bone cancer	0.00212	0.00257	CcSEcCtD
Zuclopenthixol—Erectile dysfunction—Methotrexate—bone cancer	0.00211	0.00256	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Methotrexate—bone cancer	0.00209	0.00254	CcSEcCtD
Zuclopenthixol—Breast disorder—Doxorubicin—bone cancer	0.00207	0.00251	CcSEcCtD
Zuclopenthixol—Decreased appetite—Cisplatin—bone cancer	0.00206	0.0025	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Doxorubicin—bone cancer	0.00205	0.00249	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Cisplatin—bone cancer	0.00205	0.00249	CcSEcCtD
Zuclopenthixol—Drowsiness—Methotrexate—bone cancer	0.00204	0.00248	CcSEcCtD
Zuclopenthixol—Trazodone—CYP3A4—bone cancer	0.00204	0.133	CrCbGaD
Zuclopenthixol—Pancytopenia—Epirubicin—bone cancer	0.00204	0.00247	CcSEcCtD
Zuclopenthixol—Pain—Cisplatin—bone cancer	0.00203	0.00246	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.00202	0.00245	CcSEcCtD
Zuclopenthixol—Dysuria—Epirubicin—bone cancer	0.00201	0.00243	CcSEcCtD
Zuclopenthixol—Neutropenia—Epirubicin—bone cancer	0.00201	0.00243	CcSEcCtD
Zuclopenthixol—Eosinophilia—Doxorubicin—bone cancer	0.00196	0.00238	CcSEcCtD
Zuclopenthixol—Sweating—Methotrexate—bone cancer	0.00196	0.00237	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Epirubicin—bone cancer	0.00196	0.00237	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Cisplatin—bone cancer	0.00196	0.00237	CcSEcCtD
Zuclopenthixol—Weight increased—Epirubicin—bone cancer	0.00195	0.00237	CcSEcCtD
Zuclopenthixol—Weight decreased—Epirubicin—bone cancer	0.00194	0.00235	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Epirubicin—bone cancer	0.00193	0.00234	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Methotrexate—bone cancer	0.00193	0.00234	CcSEcCtD
Zuclopenthixol—Drowsiness—Epirubicin—bone cancer	0.00191	0.00232	CcSEcCtD
Zuclopenthixol—Pipotiazine—CYP3A4—bone cancer	0.00191	0.124	CrCbGaD
Zuclopenthixol—Agranulocytosis—Methotrexate—bone cancer	0.00191	0.00231	CcSEcCtD
Zuclopenthixol—Pancytopenia—Doxorubicin—bone cancer	0.00188	0.00228	CcSEcCtD
Zuclopenthixol—Body temperature increased—Cisplatin—bone cancer	0.00188	0.00228	CcSEcCtD
Zuclopenthixol—Jaundice—Epirubicin—bone cancer	0.00186	0.00226	CcSEcCtD
Zuclopenthixol—Neutropenia—Doxorubicin—bone cancer	0.00186	0.00225	CcSEcCtD
Zuclopenthixol—Dysuria—Doxorubicin—bone cancer	0.00186	0.00225	CcSEcCtD
Zuclopenthixol—Sweating—Epirubicin—bone cancer	0.00183	0.00222	CcSEcCtD
Zuclopenthixol—Prochlorperazine—CYP3A4—bone cancer	0.00183	0.119	CrCbGaD
Zuclopenthixol—Urinary tract disorder—Methotrexate—bone cancer	0.00181	0.0022	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Doxorubicin—bone cancer	0.00181	0.0022	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Epirubicin—bone cancer	0.00181	0.00219	CcSEcCtD
Zuclopenthixol—Weight increased—Doxorubicin—bone cancer	0.00181	0.00219	CcSEcCtD
Zuclopenthixol—Urethral disorder—Methotrexate—bone cancer	0.0018	0.00218	CcSEcCtD
Zuclopenthixol—HRH1—tendon—bone cancer	0.0018	0.0113	CbGeAlD
Zuclopenthixol—Weight decreased—Doxorubicin—bone cancer	0.00179	0.00218	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Doxorubicin—bone cancer	0.00179	0.00217	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Epirubicin—bone cancer	0.00178	0.00216	CcSEcCtD
Zuclopenthixol—Drowsiness—Doxorubicin—bone cancer	0.00177	0.00214	CcSEcCtD
Zuclopenthixol—Visual impairment—Methotrexate—bone cancer	0.00177	0.00214	CcSEcCtD
Zuclopenthixol—ADRA2A—tendon—bone cancer	0.00176	0.0111	CbGeAlD
Zuclopenthixol—Hypersensitivity—Cisplatin—bone cancer	0.00175	0.00212	CcSEcCtD
Zuclopenthixol—Jaundice—Doxorubicin—bone cancer	0.00172	0.00209	CcSEcCtD
Zuclopenthixol—Eye disorder—Methotrexate—bone cancer	0.00171	0.00208	CcSEcCtD
Zuclopenthixol—Tinnitus—Methotrexate—bone cancer	0.00171	0.00207	CcSEcCtD
Zuclopenthixol—Asthenia—Cisplatin—bone cancer	0.0017	0.00207	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Methotrexate—bone cancer	0.0017	0.00206	CcSEcCtD
Zuclopenthixol—ADRA2A—spinal cord—bone cancer	0.0017	0.0107	CbGeAlD
Zuclopenthixol—Sweating—Doxorubicin—bone cancer	0.0017	0.00206	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Epirubicin—bone cancer	0.00169	0.00205	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Epirubicin—bone cancer	0.00169	0.00205	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Epirubicin—bone cancer	0.00169	0.00204	CcSEcCtD
Zuclopenthixol—Urethral disorder—Epirubicin—bone cancer	0.00168	0.00204	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Doxorubicin—bone cancer	0.00167	0.00203	CcSEcCtD
Zuclopenthixol—Angiopathy—Methotrexate—bone cancer	0.00166	0.00202	CcSEcCtD
Zuclopenthixol—Immune system disorder—Methotrexate—bone cancer	0.00166	0.00201	CcSEcCtD
Zuclopenthixol—Visual impairment—Epirubicin—bone cancer	0.00165	0.00201	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Doxorubicin—bone cancer	0.00165	0.002	CcSEcCtD
Zuclopenthixol—Diarrhoea—Cisplatin—bone cancer	0.00162	0.00197	CcSEcCtD
Zuclopenthixol—Mental disorder—Methotrexate—bone cancer	0.00161	0.00195	CcSEcCtD
Zuclopenthixol—Eye disorder—Epirubicin—bone cancer	0.0016	0.00194	CcSEcCtD
Zuclopenthixol—Tinnitus—Epirubicin—bone cancer	0.0016	0.00194	CcSEcCtD
Zuclopenthixol—Erythema—Methotrexate—bone cancer	0.0016	0.00194	CcSEcCtD
Zuclopenthixol—Malnutrition—Methotrexate—bone cancer	0.0016	0.00194	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Epirubicin—bone cancer	0.00159	0.00193	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—bone cancer	0.00157	0.0019	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—bone cancer	0.00156	0.0019	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—bone cancer	0.00156	0.00189	CcSEcCtD
Zuclopenthixol—Angiopathy—Epirubicin—bone cancer	0.00156	0.00189	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—bone cancer	0.00156	0.00189	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—bone cancer	0.00155	0.00188	CcSEcCtD
Zuclopenthixol—Arrhythmia—Epirubicin—bone cancer	0.00153	0.00186	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—bone cancer	0.00153	0.00186	CcSEcCtD
Zuclopenthixol—Vomiting—Cisplatin—bone cancer	0.00151	0.00183	CcSEcCtD
Zuclopenthixol—Vision blurred—Methotrexate—bone cancer	0.0015	0.00182	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—bone cancer	0.0015	0.00182	CcSEcCtD
Zuclopenthixol—HTR2A—tendon—bone cancer	0.0015	0.00944	CbGeAlD
Zuclopenthixol—Rash—Cisplatin—bone cancer	0.0015	0.00181	CcSEcCtD
Zuclopenthixol—Dermatitis—Cisplatin—bone cancer	0.0015	0.00181	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—bone cancer	0.00149	0.00181	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—bone cancer	0.00149	0.00181	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—bone cancer	0.00148	0.0018	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Methotrexate—bone cancer	0.00148	0.0018	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—bone cancer	0.00148	0.0018	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—bone cancer	0.00147	0.00179	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—bone cancer	0.00147	0.00178	CcSEcCtD
Zuclopenthixol—Tension—Epirubicin—bone cancer	0.00147	0.00178	CcSEcCtD
Zuclopenthixol—Nervousness—Epirubicin—bone cancer	0.00145	0.00176	CcSEcCtD
Zuclopenthixol—HTR2A—spinal cord—bone cancer	0.00145	0.0091	CbGeAlD
Zuclopenthixol—Angiopathy—Doxorubicin—bone cancer	0.00144	0.00175	CcSEcCtD
Zuclopenthixol—Malaise—Methotrexate—bone cancer	0.00144	0.00175	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—bone cancer	0.00143	0.00174	CcSEcCtD
Zuclopenthixol—Vertigo—Methotrexate—bone cancer	0.00143	0.00174	CcSEcCtD
Zuclopenthixol—Leukopenia—Methotrexate—bone cancer	0.00143	0.00173	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—bone cancer	0.00142	0.00172	CcSEcCtD
Zuclopenthixol—Nausea—Cisplatin—bone cancer	0.00141	0.00171	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—bone cancer	0.00141	0.00171	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—bone cancer	0.00139	0.00169	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—bone cancer	0.00139	0.00168	CcSEcCtD
Zuclopenthixol—Convulsion—Methotrexate—bone cancer	0.00138	0.00168	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—bone cancer	0.00138	0.00168	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—bone cancer	0.00138	0.00168	CcSEcCtD
Zuclopenthixol—Agitation—Epirubicin—bone cancer	0.00137	0.00166	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—bone cancer	0.00136	0.00165	CcSEcCtD
Zuclopenthixol—Myalgia—Methotrexate—bone cancer	0.00136	0.00165	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—bone cancer	0.00136	0.00164	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00135	0.00164	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—bone cancer	0.00135	0.00163	CcSEcCtD
Zuclopenthixol—Discomfort—Methotrexate—bone cancer	0.00134	0.00163	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—bone cancer	0.00134	0.00163	CcSEcCtD
Zuclopenthixol—Vertigo—Epirubicin—bone cancer	0.00134	0.00163	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—bone cancer	0.00134	0.00162	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—bone cancer	0.00134	0.00162	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—bone cancer	0.00132	0.0016	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Epirubicin—bone cancer	0.00131	0.00159	CcSEcCtD
Zuclopenthixol—Perphenazine—CYP3A4—bone cancer	0.00131	0.085	CrCbGaD
Zuclopenthixol—Anaphylactic shock—Methotrexate—bone cancer	0.0013	0.00158	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—bone cancer	0.0013	0.00158	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—bone cancer	0.00129	0.00157	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—bone cancer	0.00129	0.00156	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—bone cancer	0.00128	0.00155	CcSEcCtD
Zuclopenthixol—Quetiapine—CYP3A4—bone cancer	0.00128	0.0834	CrCbGaD
Zuclopenthixol—Nervous system disorder—Methotrexate—bone cancer	0.00128	0.00155	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Methotrexate—bone cancer	0.00128	0.00155	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—bone cancer	0.00127	0.00154	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—bone cancer	0.00127	0.00154	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—bone cancer	0.00127	0.00154	CcSEcCtD
Zuclopenthixol—Skin disorder—Methotrexate—bone cancer	0.00127	0.00153	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00126	0.00153	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Methotrexate—bone cancer	0.00126	0.00153	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—bone cancer	0.00126	0.00152	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—bone cancer	0.00125	0.00151	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—bone cancer	0.00124	0.00151	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—bone cancer	0.00124	0.00151	CcSEcCtD
Zuclopenthixol—Anorexia—Methotrexate—bone cancer	0.00124	0.00151	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—bone cancer	0.00124	0.0015	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—bone cancer	0.00124	0.0015	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—bone cancer	0.00122	0.00148	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—bone cancer	0.00122	0.00148	CcSEcCtD
Zuclopenthixol—Hypotension—Methotrexate—bone cancer	0.00122	0.00148	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—bone cancer	0.00122	0.00147	CcSEcCtD
Zuclopenthixol—Shock—Epirubicin—bone cancer	0.0012	0.00145	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—bone cancer	0.0012	0.00145	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—bone cancer	0.0012	0.00145	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—bone cancer	0.00119	0.00145	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—bone cancer	0.00119	0.00145	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—bone cancer	0.00119	0.00144	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00119	0.00144	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—bone cancer	0.00118	0.00144	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—bone cancer	0.00118	0.00143	CcSEcCtD
Zuclopenthixol—Insomnia—Methotrexate—bone cancer	0.00118	0.00143	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—bone cancer	0.00118	0.00143	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—bone cancer	0.00117	0.00142	CcSEcCtD
Zuclopenthixol—Paraesthesia—Methotrexate—bone cancer	0.00117	0.00142	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00117	0.00142	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—bone cancer	0.00116	0.00141	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—bone cancer	0.00116	0.00141	CcSEcCtD
Zuclopenthixol—Dyspnoea—Methotrexate—bone cancer	0.00116	0.00141	CcSEcCtD
Zuclopenthixol—Somnolence—Methotrexate—bone cancer	0.00116	0.0014	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—bone cancer	0.00115	0.0014	CcSEcCtD
Zuclopenthixol—Dyspepsia—Methotrexate—bone cancer	0.00115	0.00139	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—bone cancer	0.00114	0.00138	CcSEcCtD
Zuclopenthixol—Decreased appetite—Methotrexate—bone cancer	0.00113	0.00137	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—bone cancer	0.00113	0.00137	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Methotrexate—bone cancer	0.00112	0.00136	CcSEcCtD
Zuclopenthixol—Fatigue—Methotrexate—bone cancer	0.00112	0.00136	CcSEcCtD
Zuclopenthixol—Pain—Methotrexate—bone cancer	0.00111	0.00135	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00111	0.00135	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—bone cancer	0.00111	0.00135	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—bone cancer	0.00111	0.00134	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—bone cancer	0.0011	0.00134	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—bone cancer	0.0011	0.00134	CcSEcCtD
Zuclopenthixol—Clozapine—CYP3A4—bone cancer	0.0011	0.0717	CrCbGaD
Zuclopenthixol—Tachycardia—Doxorubicin—bone cancer	0.0011	0.00133	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—bone cancer	0.0011	0.00133	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—bone cancer	0.00109	0.00133	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—bone cancer	0.00109	0.00132	CcSEcCtD
Zuclopenthixol—Dyspnoea—Epirubicin—bone cancer	0.00109	0.00132	CcSEcCtD
Zuclopenthixol—Somnolence—Epirubicin—bone cancer	0.00108	0.00131	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—bone cancer	0.00108	0.0013	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Methotrexate—bone cancer	0.00107	0.0013	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—bone cancer	0.00107	0.0013	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Methotrexate—bone cancer	0.00107	0.00129	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—bone cancer	0.00106	0.00129	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—bone cancer	0.00105	0.00128	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—bone cancer	0.00105	0.00128	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—bone cancer	0.00105	0.00127	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—bone cancer	0.00104	0.00126	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—bone cancer	0.00104	0.00126	CcSEcCtD
Zuclopenthixol—Chlorpromazine—CYP3A4—bone cancer	0.00104	0.0675	CrCbGaD
Zuclopenthixol—Body temperature increased—Methotrexate—bone cancer	0.00103	0.00125	CcSEcCtD
Zuclopenthixol—Abdominal pain—Methotrexate—bone cancer	0.00103	0.00125	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00103	0.00125	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—bone cancer	0.00102	0.00124	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—bone cancer	0.00101	0.00123	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—bone cancer	0.00101	0.00122	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—bone cancer	0.001	0.00122	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—bone cancer	0.001	0.00122	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—bone cancer	0.000997	0.00121	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—bone cancer	0.000993	0.0012	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—bone cancer	0.000981	0.00119	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000974	0.00118	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—bone cancer	0.000973	0.00118	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—bone cancer	0.000965	0.00117	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—bone cancer	0.000965	0.00117	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—bone cancer	0.000964	0.00117	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—bone cancer	0.000964	0.00117	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Methotrexate—bone cancer	0.00096	0.00116	CcSEcCtD
Zuclopenthixol—Asthenia—Methotrexate—bone cancer	0.000935	0.00113	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—bone cancer	0.00093	0.00113	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—bone cancer	0.000923	0.00112	CcSEcCtD
Zuclopenthixol—Pruritus—Methotrexate—bone cancer	0.000922	0.00112	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Epirubicin—bone cancer	0.000898	0.00109	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—bone cancer	0.000892	0.00108	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—bone cancer	0.000892	0.00108	CcSEcCtD
Zuclopenthixol—Diarrhoea—Methotrexate—bone cancer	0.000892	0.00108	CcSEcCtD
Zuclopenthixol—Asthenia—Epirubicin—bone cancer	0.000875	0.00106	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—bone cancer	0.000863	0.00105	CcSEcCtD
Zuclopenthixol—Dizziness—Methotrexate—bone cancer	0.000862	0.00104	CcSEcCtD
Zuclopenthixol—Diarrhoea—Epirubicin—bone cancer	0.000834	0.00101	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—bone cancer	0.000831	0.00101	CcSEcCtD
Zuclopenthixol—Vomiting—Methotrexate—bone cancer	0.000828	0.001	CcSEcCtD
Zuclopenthixol—Rash—Methotrexate—bone cancer	0.000822	0.000996	CcSEcCtD
Zuclopenthixol—Dermatitis—Methotrexate—bone cancer	0.000821	0.000995	CcSEcCtD
Zuclopenthixol—Headache—Methotrexate—bone cancer	0.000816	0.00099	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—bone cancer	0.000809	0.000981	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—bone cancer	0.000806	0.000978	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—bone cancer	0.000798	0.000968	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—bone cancer	0.000775	0.00094	CcSEcCtD
Zuclopenthixol—Nausea—Methotrexate—bone cancer	0.000774	0.000938	CcSEcCtD
Zuclopenthixol—Diarrhoea—Doxorubicin—bone cancer	0.000772	0.000936	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—bone cancer	0.000769	0.000932	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—bone cancer	0.000768	0.000931	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—bone cancer	0.000764	0.000926	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—bone cancer	0.000746	0.000904	CcSEcCtD
Zuclopenthixol—Nausea—Epirubicin—bone cancer	0.000724	0.000878	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—bone cancer	0.000717	0.00087	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—bone cancer	0.000711	0.000862	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—bone cancer	0.000711	0.000862	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—bone cancer	0.000707	0.000857	CcSEcCtD
Zuclopenthixol—Nausea—Doxorubicin—bone cancer	0.00067	0.000812	CcSEcCtD
Zuclopenthixol—DRD1—Signaling by GPCR—GRM4—bone cancer	2.54e-06	0.00307	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—RGS1—bone cancer	2.54e-06	0.00307	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—GRM1—bone cancer	2.42e-06	0.00293	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—GNA11—bone cancer	2.35e-06	0.00284	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Biological oxidations—CYP3A4—bone cancer	2.34e-06	0.00283	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—SMO—bone cancer	2.33e-06	0.00282	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	2.31e-06	0.00279	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR ligand binding—SMO—bone cancer	2.28e-06	0.00276	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—GRM4—bone cancer	2.26e-06	0.00273	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—RGS1—bone cancer	2.26e-06	0.00273	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR ligand binding—SMO—bone cancer	2.24e-06	0.00271	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR ligand binding—SMO—bone cancer	2.24e-06	0.00271	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—GRM1—bone cancer	2.2e-06	0.00266	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—SMO—bone cancer	2.2e-06	0.00266	CbGpPWpGaD
Zuclopenthixol—DRD2—Circadian rythm related genes—CDK4—bone cancer	2.19e-06	0.00265	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—NDUFA12—bone cancer	2.15e-06	0.0026	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—GNA11—bone cancer	2.13e-06	0.00258	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—IL3—bone cancer	2.13e-06	0.00257	CbGpPWpGaD
Zuclopenthixol—ADRA1A—AMPK Signaling—TP53—bone cancer	2.11e-06	0.00256	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—GRM4—bone cancer	2.11e-06	0.00255	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—RGS1—bone cancer	2.11e-06	0.00255	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—GRM4—bone cancer	2.07e-06	0.00251	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—RGS1—bone cancer	2.07e-06	0.00251	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—GRM4—bone cancer	2.07e-06	0.0025	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—RGS1—bone cancer	2.07e-06	0.0025	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—SMO—bone cancer	2.04e-06	0.00247	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—GRM4—bone cancer	2.03e-06	0.00246	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—RGS1—bone cancer	2.03e-06	0.00246	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Biological oxidations—GSTP1—bone cancer	2e-06	0.00242	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	1.97e-06	0.00238	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—GRM1—bone cancer	1.96e-06	0.00236	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—IL3—bone cancer	1.93e-06	0.00234	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—GRM4—bone cancer	1.92e-06	0.00232	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—RGS1—bone cancer	1.92e-06	0.00232	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—RGS1—bone cancer	1.89e-06	0.00228	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—GRM4—bone cancer	1.89e-06	0.00228	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—GRM4—bone cancer	1.88e-06	0.00228	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—RGS1—bone cancer	1.88e-06	0.00228	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—RGS1—bone cancer	1.88e-06	0.00227	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—GRM4—bone cancer	1.88e-06	0.00227	CbGpPWpGaD
Zuclopenthixol—DRD1—Circadian rythm related genes—JUN—bone cancer	1.87e-06	0.00226	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—RGS1—bone cancer	1.85e-06	0.00223	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—GRM4—bone cancer	1.85e-06	0.00223	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—GRM1—bone cancer	1.83e-06	0.00221	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—SPARC—bone cancer	1.82e-06	0.00221	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—GNA11—bone cancer	1.81e-06	0.00219	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—SMO—bone cancer	1.8e-06	0.00218	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—GRM1—bone cancer	1.8e-06	0.00218	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—GRM1—bone cancer	1.8e-06	0.00217	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—NT5C3A—bone cancer	1.78e-06	0.00215	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—GRM1—bone cancer	1.76e-06	0.00213	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—RGS1—bone cancer	1.74e-06	0.0021	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—GRM4—bone cancer	1.74e-06	0.0021	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—RGS1—bone cancer	1.71e-06	0.00207	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—GRM4—bone cancer	1.71e-06	0.00207	CbGpPWpGaD
Zuclopenthixol—HTR2A—SIDS Susceptibility Pathways—JUN—bone cancer	1.7e-06	0.00206	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—GNA11—bone cancer	1.67e-06	0.00202	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—GRM1—bone cancer	1.66e-06	0.00201	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—GNA11—bone cancer	1.65e-06	0.00199	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—IL3—bone cancer	1.64e-06	0.00199	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—GRM1—bone cancer	1.64e-06	0.00198	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—GRM1—bone cancer	1.63e-06	0.00198	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—GRM1—bone cancer	1.63e-06	0.00197	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—GRM1—bone cancer	1.6e-06	0.00193	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—GNA11—bone cancer	1.56e-06	0.00189	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—SMO—bone cancer	1.55e-06	0.00187	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—IL3—bone cancer	1.51e-06	0.00183	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—GRM1—bone cancer	1.51e-06	0.00182	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—GRM4—bone cancer	1.5e-06	0.00181	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—RGS1—bone cancer	1.5e-06	0.00181	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—IL3—bone cancer	1.49e-06	0.0018	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—GRM1—bone cancer	1.49e-06	0.0018	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—GNA11—bone cancer	1.42e-06	0.00171	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—IL3—bone cancer	1.41e-06	0.00171	CbGpPWpGaD
Zuclopenthixol—DRD2—Circadian rythm related genes—JUN—bone cancer	1.41e-06	0.00171	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NDUFA12—bone cancer	1.4e-06	0.00169	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—SMO—bone cancer	1.38e-06	0.00167	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—GRM1—bone cancer	1.3e-06	0.00157	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—IL3—bone cancer	1.28e-06	0.00155	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—GNA11—bone cancer	1.26e-06	0.00152	CbGpPWpGaD
Zuclopenthixol—DRD1—Circadian rythm related genes—TP53—bone cancer	1.24e-06	0.00149	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—GNA11—bone cancer	1.18e-06	0.00142	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—ATF1—bone cancer	1.17e-06	0.00142	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—SMO—bone cancer	1.17e-06	0.00141	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NT5C3A—bone cancer	1.16e-06	0.0014	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—GNA11—bone cancer	1.16e-06	0.0014	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—GNA11—bone cancer	1.16e-06	0.0014	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—SMO—bone cancer	1.15e-06	0.00139	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—SMO—bone cancer	1.15e-06	0.00139	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL3—bone cancer	1.14e-06	0.00138	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—GNA11—bone cancer	1.14e-06	0.00137	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—GRM4—bone cancer	1.13e-06	0.00137	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—RGS1—bone cancer	1.13e-06	0.00137	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—SMO—bone cancer	1.13e-06	0.00136	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—GRM4—bone cancer	1.11e-06	0.00135	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—RGS1—bone cancer	1.11e-06	0.00135	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—RGS1—bone cancer	1.11e-06	0.00134	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—GRM4—bone cancer	1.11e-06	0.00134	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—GRM4—bone cancer	1.09e-06	0.00132	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—RGS1—bone cancer	1.09e-06	0.00132	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—GNA11—bone cancer	1.07e-06	0.00129	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—IL3—bone cancer	1.07e-06	0.00129	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—SMO—bone cancer	1.06e-06	0.00129	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—GNA11—bone cancer	1.05e-06	0.00128	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—GNA11—bone cancer	1.05e-06	0.00127	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—IL3—bone cancer	1.05e-06	0.00127	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—GNA11—bone cancer	1.05e-06	0.00127	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—IL3—bone cancer	1.05e-06	0.00127	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—SMO—bone cancer	1.05e-06	0.00127	CbGpPWpGaD
Zuclopenthixol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	1.04e-06	0.00125	CbGpPWpGaD
Zuclopenthixol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	1.03e-06	0.00125	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—GNA11—bone cancer	1.03e-06	0.00125	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—IL3—bone cancer	1.03e-06	0.00124	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	1.01e-06	0.00123	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—GRM4—bone cancer	1.01e-06	0.00122	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—RGS1—bone cancer	1.01e-06	0.00122	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—PLAU—bone cancer	9.92e-07	0.0012	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—GRM1—bone cancer	9.81e-07	0.00119	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TGFBR2—bone cancer	9.77e-07	0.00118	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—GNA11—bone cancer	9.73e-07	0.00118	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL3—bone cancer	9.7e-07	0.00117	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—GRM1—bone cancer	9.65e-07	0.00117	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—GRM1—bone cancer	9.63e-07	0.00116	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—GNA11—bone cancer	9.58e-07	0.00116	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—IL3—bone cancer	9.56e-07	0.00116	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL3—bone cancer	9.54e-07	0.00115	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL3—bone cancer	9.52e-07	0.00115	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—GRM1—bone cancer	9.45e-07	0.00114	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL3—bone cancer	9.35e-07	0.00113	CbGpPWpGaD
Zuclopenthixol—DRD2—Circadian rythm related genes—TP53—bone cancer	9.33e-07	0.00113	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IGF1R—bone cancer	9.19e-07	0.00111	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SMO—bone cancer	9.15e-07	0.00111	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—ATF1—bone cancer	9.04e-07	0.00109	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL3—bone cancer	8.82e-07	0.00107	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—GRM1—bone cancer	8.78e-07	0.00106	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL3—bone cancer	8.68e-07	0.00105	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—GNA11—bone cancer	8.37e-07	0.00101	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ENO2—bone cancer	7.8e-07	0.000944	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—ATF1—bone cancer	7.78e-07	0.000941	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL3—bone cancer	7.59e-07	0.000918	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TGFBR2—bone cancer	7.54e-07	0.000912	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—DHFR—bone cancer	7.24e-07	0.000875	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IGF1R—bone cancer	7.09e-07	0.000858	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SMO—bone cancer	6.91e-07	0.000835	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SMO—bone cancer	6.8e-07	0.000822	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SMO—bone cancer	6.79e-07	0.00082	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—GNA11—bone cancer	6.77e-07	0.000818	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—KIT—bone cancer	6.67e-07	0.000806	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SMO—bone cancer	6.66e-07	0.000805	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TGFBR2—bone cancer	6.49e-07	0.000785	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—GNA11—bone cancer	6.32e-07	0.000764	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—BRAF—bone cancer	6.27e-07	0.000758	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—GNA11—bone cancer	6.22e-07	0.000752	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—GNA11—bone cancer	6.21e-07	0.00075	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SMO—bone cancer	6.19e-07	0.000748	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CYP3A4—bone cancer	6.13e-07	0.000742	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IGF1R—bone cancer	6.11e-07	0.000738	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—GNA11—bone cancer	6.09e-07	0.000736	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—EGFR—bone cancer	6.07e-07	0.000734	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ATF1—bone cancer	5.88e-07	0.00071	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ATF1—bone cancer	5.78e-07	0.000699	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ATF1—bone cancer	5.77e-07	0.000697	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL3—bone cancer	5.73e-07	0.000693	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ATF1—bone cancer	5.66e-07	0.000684	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—GNA11—bone cancer	5.66e-07	0.000684	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL3—bone cancer	5.64e-07	0.000682	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL3—bone cancer	5.63e-07	0.00068	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL3—bone cancer	5.52e-07	0.000667	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ATF1—bone cancer	5.26e-07	0.000636	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MDM2—bone cancer	5.25e-07	0.000635	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—GSTP1—bone cancer	5.25e-07	0.000634	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KIT—bone cancer	5.15e-07	0.000622	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL3—bone cancer	5.13e-07	0.00062	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ENO2—bone cancer	5.09e-07	0.000615	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TGFBR2—bone cancer	4.9e-07	0.000593	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—BRAF—bone cancer	4.84e-07	0.000585	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TGFBR2—bone cancer	4.82e-07	0.000583	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TGFBR2—bone cancer	4.81e-07	0.000582	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TGFBR2—bone cancer	4.72e-07	0.000571	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—DHFR—bone cancer	4.72e-07	0.00057	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—EGFR—bone cancer	4.69e-07	0.000567	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IGF1R—bone cancer	4.61e-07	0.000557	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—JUN—bone cancer	4.56e-07	0.000552	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IGF1R—bone cancer	4.54e-07	0.000549	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IGF1R—bone cancer	4.53e-07	0.000547	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IGF1R—bone cancer	4.44e-07	0.000537	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MMP9—bone cancer	4.44e-07	0.000537	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KIT—bone cancer	4.43e-07	0.000535	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GNA11—bone cancer	4.41e-07	0.000533	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TGFBR2—bone cancer	4.39e-07	0.00053	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—BRAF—bone cancer	4.16e-07	0.000503	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IGF1R—bone cancer	4.13e-07	0.000499	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MDM2—bone cancer	4.05e-07	0.00049	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—EGFR—bone cancer	4.04e-07	0.000488	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP3A4—bone cancer	4e-07	0.000483	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—TP53—bone cancer	3.99e-07	0.000482	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—EGFR—bone cancer	3.59e-07	0.000434	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—JUN—bone cancer	3.52e-07	0.000426	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MDM2—bone cancer	3.49e-07	0.000422	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MMP9—bone cancer	3.43e-07	0.000414	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GSTP1—bone cancer	3.42e-07	0.000413	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KIT—bone cancer	3.34e-07	0.000404	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KIT—bone cancer	3.29e-07	0.000398	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KIT—bone cancer	3.28e-07	0.000397	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KIT—bone cancer	3.22e-07	0.00039	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—BRAF—bone cancer	3.14e-07	0.00038	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—BRAF—bone cancer	3.09e-07	0.000374	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—BRAF—bone cancer	3.09e-07	0.000373	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—EGFR—bone cancer	3.05e-07	0.000368	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—JUN—bone cancer	3.03e-07	0.000367	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—BRAF—bone cancer	3.03e-07	0.000366	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TP53—bone cancer	3.01e-07	0.000364	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—EGFR—bone cancer	3e-07	0.000362	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KIT—bone cancer	2.99e-07	0.000362	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—EGFR—bone cancer	2.99e-07	0.000362	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MMP9—bone cancer	2.95e-07	0.000357	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—EGFR—bone cancer	2.94e-07	0.000355	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—BRAF—bone cancer	2.81e-07	0.00034	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—EGFR—bone cancer	2.77e-07	0.000335	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—EGFR—bone cancer	2.73e-07	0.00033	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—bone cancer	2.72e-07	0.000329	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MDM2—bone cancer	2.63e-07	0.000318	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MDM2—bone cancer	2.59e-07	0.000313	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MDM2—bone cancer	2.59e-07	0.000313	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MDM2—bone cancer	2.54e-07	0.000307	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EGFR—bone cancer	2.38e-07	0.000288	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MDM2—bone cancer	2.36e-07	0.000285	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—bone cancer	2.33e-07	0.000281	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—JUN—bone cancer	2.29e-07	0.000277	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—JUN—bone cancer	2.25e-07	0.000272	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—JUN—bone cancer	2.25e-07	0.000272	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MMP9—bone cancer	2.23e-07	0.000269	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—JUN—bone cancer	2.21e-07	0.000267	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MMP9—bone cancer	2.19e-07	0.000265	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MMP9—bone cancer	2.19e-07	0.000264	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MMP9—bone cancer	2.15e-07	0.000259	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—JUN—bone cancer	2.05e-07	0.000248	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—bone cancer	2e-07	0.000242	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP9—bone cancer	1.99e-07	0.000241	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EGFR—bone cancer	1.8e-07	0.000218	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—bone cancer	1.77e-07	0.000214	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EGFR—bone cancer	1.77e-07	0.000214	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EGFR—bone cancer	1.77e-07	0.000214	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EGFR—bone cancer	1.73e-07	0.00021	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGFR—bone cancer	1.61e-07	0.000195	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—bone cancer	1.51e-07	0.000183	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—bone cancer	1.49e-07	0.00018	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—bone cancer	1.48e-07	0.000179	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—bone cancer	1.46e-07	0.000176	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—bone cancer	1.35e-07	0.000164	CbGpPWpGaD
